Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23919059 | 0.88 | GNAO1 (0.44) | GNAO1SIGMAR1CACNA1IKCNH2ACHE | |
| SCHEMBL23919057 | 0.84 | SIGMAR1 (0.41) | GNAO1SIGMAR1RAD52CNR1POLB | |
| SCHEMBL21472825 | 0.84 | ACHE (0.39) | GNAO1SIGMAR1ACHERAD52CHRM5 | |
| SCHEMBL26972265 | 0.84 | CHRM5 (0.53) | CACNA1IKCNH2ACHECNR1SMN1; SMN2 | |
| SCHEMBL22166533 | 0.84 | CACNA1I (0.40) | GNAO1CACNA1IKCNH2ACHECNR1 | |
| SCHEMBL2600051 | 0.83 | SIGMAR1 (0.52) | GNAO1SIGMAR1RAD52POLBSMN1; SMN2 | |
| SCHEMBL20314499 | 0.83 | CACNA1I (0.39) | GNAO1CACNA1IKCNH2ACHECNR1 | |
| SCHEMBL23867106 | 0.82 | GNAO1 (0.49) | GNAO1ACHERAD52POLBSMN1; SMN2 | |
| SCHEMBL25026639 | 0.82 | NCF1 (0.43) | GNAO1SIGMAR1ACHERAD52POLB | |
| SCHEMBL20314514 | 0.81 | CACNA1I (0.39) | GNAO1CACNA1IKCNH2ACHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | GNAO1 2111/4885SIGMAR1 3941/4885CACNA1I 4058/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | GNAO1 2111/4885SIGMAR1 3941/4885CACNA1I 4058/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | GNAO1 1639/4885SIGMAR1 3038/4885CACNA1I 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.